Taking stock of the drug industry, from the lab to the medicine chestApril 17, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Maddie McGarvey for STAT STAT+ | A bellwether moment: Once a distant dream, gene therapy for Duchenne nears historic decision A looming verdict on Sarepta's therapy has made this perhaps the most consequential moment in the history of Duchenne. By Jason Mast and Adam Feuerstein Q&A: What does it mean when a clinical trial is delayed? More than you think STAT sat down with clinical trials expert Frank David to talk about why trial delays are important and how trials have changed over time. By Erica Goode STAT+ | Moderna-Merck mRNA cancer vaccine shows promise in combination with melanoma drug A new study provides the strongest evidence yet that a personalized cancer vaccine can offer clinical benefit to patients. By Angus Chen Mel Evans/AP STAT+ | Merck to acquire Prometheus Biosciences, maker of autoimmune drugs, for $10.8 billion The $10.8 billion deal gives Merck access to a drug, PRA023, which is being developed for inflammatory bowel diseases. By Adam Feuerstein Opinion: OTC naloxone is a baby step toward making the life-saving medication accessible Now that naloxone will be available OTC, we need more substantial efforts to reduce cost and increase access to this lifesaving medication. By Jonathan JK Stoltman and Mishka Terplan More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments